Welcome to our dedicated page for Trinity Biotech plc news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech plc stock.
Trinity Biotech plc (NASDAQ: TRIB) is an international leader in the diagnostics industry, focusing on the development, manufacturing, and marketing of clinical diagnostic products for both clinical laboratories and point-of-care settings. Headquartered in Ireland, Trinity Biotech has been at the forefront of the industry since its formation in 1992, employing over 350 people and offering more than 400 products to customers in 80 countries.
Through a blend of organic growth and strategic acquisitions, Trinity Biotech has built a comprehensive portfolio of diagnostic products. These include test kits for the detection of infectious diseases, sexually transmitted diseases, autoimmune and hemoglobin disorders, and tools for diabetes monitoring and control. The company also supplies raw materials to the life sciences industry, expanding its influence and reach within the global market.
Trinity Biotech's product lineup features well-known brands such as Recombigen, Unigold, MarBlot, Mardx, and Immublot. The company's operations are geographically segmented into the Americas and the rest of the world, with a significant portion of its revenue derived from the Americas.
Recent developments have seen Trinity Biotech making significant strides in the diabetes management sector. The company recently acquired biosensor technology from Waveform Technologies Inc., marking its entry into the wearable biosensor market. This new venture aims to develop a range of biosensor devices, starting with a continuous glucose monitoring (CGM) product. To lead this initiative, Trinity Biotech appointed Avinash Kale as the Continuous Glucose Monitor Programme Director. Mr. Kale brings extensive experience in MedTech R&D and will play a pivotal role in advancing the company's CGM technology.
The company's commitment to innovation and excellence is evident in its ongoing projects and partnerships. Trinity Biotech continues to expand its product offerings and improve existing technologies to meet the needs of healthcare providers and patients worldwide. The company's dedication to quality and sustainability ensures that its diagnostic solutions remain at the cutting edge of the industry.
Trinity Biotech's financial performance for the fiscal year 2023 has been robust, with the company reporting significant growth and key business updates. The company's strategic focus on diabetes management solutions and human diagnostics positions it well for future success and shareholder value creation. For more details, visit Trinity Biotech's website.
Trinity Biotech plc (Nasdaq: TRIB) has announced increased orders for its TrinScreen HIV product, leading to an upward revision of its 2024 sales guidance. The company now expects TrinScreen HIV sales to reach approximately $10 million in 2024, up from the previous estimate of $8 million. This increase is attributed to strong demand and successful scaling of production capacity.
Additionally, Trinity Biotech has increased manufacturing capacity for FlexTrans™, its FDA 510(k) cleared viral transport medium, in anticipation of potential increased demand due to the WHO's declaration of Mpox as a Public Health Emergency of International Concern. The company aims to contribute to diagnostic testing for this global health threat.
Trinity Biotech plc (Nasdaq: TRIB) has appointed David Ouston as Biosensor Marketing Director to drive growth for its innovative continuous glucose monitoring (CGM) technology. Ouston brings 16 years of experience in the glucose monitoring and diabetes health sectors, including roles at Johnson & Johnson and LifeScan. CEO John Gillard emphasized the importance of this strategic appointment for Trinity's long-term growth, particularly in rapidly expanding diabetes and wellness markets.
Ouston expressed enthusiasm for joining Trinity Biotech, highlighting the company's vision for an accessible and innovative CGM in global markets. He aims to leverage his extensive global leadership experience in promotion and market access strategies for diabetes management devices to help deliver Trinity's disruptive solution worldwide.
Trinity Biotech plc (Nasdaq: TRIB) reported strong Q2 2024 financial results, with total revenues of $15.8 million, up 14% year-over-year and 7.7% quarter-over-quarter. The growth was driven by strong demand in the TrinScreen HIV business. Point-of-Care product revenue reached $4.6 million, growing 119% year-over-year and 53% quarter-over-quarter. The company reiterated its guidance to achieve approximately $20 million of annualized run-rate EBITDASO on annualized run-rate revenues of about $75 million by Q2 2025. Trinity Biotech continues to make progress on its Comprehensive Transformation Plan, including manufacturing consolidation, supply chain optimization, and corporate services centralization. The company is also advancing its next-generation Continuous Glucose Monitoring system development.
Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company specializing in diabetes management solutions and human diagnostics, has announced it will release its Q2 2024 financial results on Wednesday, August 14, 2024. The company will host a conference call at 8:30 AM ET on the same day to discuss the results.
Investors and interested parties can access the call through various methods:
- US Toll-Free: 1-877-407-0784
- International: 1-201-689-8560
- Conference ID: 13748426
- Webcast link available
- Call me™ feature: https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6
Trinity Biotech plc (Nasdaq: TRIB), a biotechnology company specializing in human diagnostics and diabetes management solutions, has secured an extension from Nasdaq to demonstrate compliance with listing requirements. The company had received a deficiency letter on November 21, 2023, due to its market value of publicly held shares (MVPHS) falling below the $15 million threshold for 30 consecutive business days. After meeting with the Nasdaq Hearings Panel on July 16, 2024, Trinity Biotech was granted an extension until October 31, 2024, to meet the MVPHS Requirement and maintain its listing on The Nasdaq Global Select Market.
Trinity Biotech (Nasdaq: TRIB) announces preliminary Q2 2024 revenues expected between $15.5-$16.0 million, showing significant growth from $13.9 million in Q2 2023. The company reiterates its financial guidance of $20 million annualized run-rate EBITDASO on $75 million annualized run-rate revenues by Q2 2025. Trinity also enters a UK distribution agreement with MedScience, effective August 1, 2024, covering clinical chemistry, infectious disease, and autoimmune products. This partnership aims to expand Trinity's presence in the UK market and support growth objectives. The company attributes revenue growth to initiatives like the new HIV screening product, TrinScreen HIV. Full Q2 2024 earnings report is expected mid-August, providing updates on the Comprehensive Transformation Plan and continuous glucose monitor (CGM) program.
Trinity Biotech (Nasdaq: TRIB) announced the appointment of Louise Tallon as its new Chief Financial Officer (CFO), effective August 2024. Tallon, who is currently Head of Group Finance at Inizio and has over 19 years of experience in the life sciences industry, will succeed Des Fitzgerald, the interim CFO since December 2023. CEO John Gillard expressed confidence in Tallon's ability to drive the company’s transformation and growth, particularly in the launch of their next-generation continuous glucose monitor (CGM). The company reiterated its financial guidance, aiming for $20 million in annualized EBITDASO1 on $75 million in annualized revenues by Q2 2025. Additionally, Ms. Tallon will take over the responsibilities of the departing Chief Accounting Officer, Simon Dunne.
Trinity Biotech (Nasdaq: TRIB) has received regulatory approval to begin its European pre-pivotal trial for its next-generation continuous glucose monitoring (CGM) system. The trial aims to optimize device performance ahead of a pivotal trial scheduled for 2025. The pre-pivotal trial, set to start imminently and expected to conclude by the end of July, will evaluate the analytical performance of the CGM technology enhancements made by Trinity Biotech following its acquisition earlier this year. The collected data will be used to refine the device further. John Gillard, President and CEO, emphasized the importance of the CGM solution and AI-driven analytics as long-term growth drivers for the company.
Trinity Biotech (Nasdaq: TRIB), a commercial-stage biotechnology firm specializing in diabetes management solutions and diagnostics, announces its senior management will attend the 84th Scientific Sessions of the American Diabetes Association. The event is scheduled for June 21-24, 2024, in Orlando, Florida. Trinity Biotech aims to advance its continuous glucose monitoring (CGM) biosensor technology and plans to host meetings with key stakeholders and potential partners. Interested parties can contact Biosensors@trinitybiotech.com for more information.
Trinity Biotech (Nasdaq: TRIB) announced the launch of its continuous glucose monitoring (CGM) microsite, https://cgm.trinitybiotech.com. The site aims to provide key stakeholders with insights into the company's vision for its recently acquired CGM biosensor technology and AI-driven health and wellness analytics platform. The CEO, John Gillard, emphasized the focus on usability, affordability, and sustainability to enhance global accessibility for diabetes management. The microsite will also offer updates on the international commercialization efforts and encourage stakeholders to sign up for newsletters and email alerts.
FAQ
What is the current stock price of Trinity Biotech plc (TRIB)?
What is the market cap of Trinity Biotech plc (TRIB)?
What does Trinity Biotech plc do?
Where is Trinity Biotech headquartered?
What recent developments have been made by Trinity Biotech?
How many products does Trinity Biotech offer?
In which markets does Trinity Biotech operate?
What are some of Trinity Biotech's product brands?
What is the significance of Trinity Biotech in the diagnostics industry?
Who is the CEO of Trinity Biotech?
What is Trinity Biotech's focus in recent years?
How can I learn more about Trinity Biotech's products and services?
